SPACE
Regimen
- Experimental
- DEB-TACE + sorafenib 400 mg BID
- Control
- DEB-TACE + placebo
Population
Intermediate-stage multinodular hepatocellular carcinoma without macrovascular invasion or extrahepatic spread
Key finding
mTTP 169 vs 166 d (HR 0.80, P=0.072, NS). DEB-TACE + sorafenib failed to meaningfully improve time-to-progression over DEB-TACE alone. Negative legacy — ended first wave of TKI+TACE enthusiasm.
Source: PMID 26809111